The US FDA Grants Clearance to Moon Surgical’s Commercial Maestro Robotic Surgery System
Shots:
- The US FDA has granted clearance to the company’s commercial version of the Maestro surgical system. It will be deployed in a Limited Market Release before a broader launch in 2025 across the US & EU
- The Maestro system can support soft tissue surgeries not covered by current telerobotic systems. It is small and adaptable which can fit into existing workflows for any laparoscopic indications and consists of an AI-based NVIDIA Holoscan platform to provide real-time benefits during surgery
- Additionally, the system has received a CE mark in Sep 2023. It has been utilized in 200 patients for general, bariatric and gynecologic surgery across 2 European pilot sites
Ref: PR Newswire | Image: Moon Surgical
Related News: Medtronic Reports the First Patient Enrollment of Hugo Robotic-Assisted Surgery System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
